STOCK TITAN

argenx SE American Depositary Shares - ARGX STOCK NEWS

Welcome to our dedicated page for argenx SE American Depositary Shares news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on argenx SE American Depositary Shares stock.

argenx SE (ARGX) is a leading global immunology company dedicated to transforming the lives of individuals suffering from severe autoimmune diseases and cancer. Originating from the Netherlands, argenx focuses on leveraging its advanced antibody engineering technology to address rare and debilitating autoimmune conditions.

One of the company’s landmark achievements is the development and approval of Vyvgart (efgartigimod), a groundbreaking treatment for generalized myasthenia gravis. Vyvgart received approval from the U.S. FDA in December 2021, followed by subsequent approvals in Europe and Japan in 2022. This therapeutic advancement underscores argenx’s commitment to delivering innovative solutions for patients with unmet medical needs.

In addition to Vyvgart, argenx continues to drive forward with several promising projects aimed at expanding its portfolio of antibody-based medicines. The company’s dedication to translating immunology breakthroughs into novel treatments is reflected in its ongoing research and development activities. Notably, argenx is advancing clinical studies on VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with a focus on delivering effective therapies to a broader patient population.

Financially, argenx is well-positioned to sustain its growth trajectory, backed by strategic partnerships and a solid pipeline of innovative products. The company collaborates with key stakeholders across the healthcare industry to enhance its research capabilities and expedite the development of new treatments.

For the latest updates and more detailed information, investors and media can contact:
Ben Petok - BPetok@argenx.com
Alexandra Roy (US) - ARoy@argenx.com
Lynn Elton (EU) - LElton@argenx.com

Rhea-AI Summary
Health Canada authorizes VYVGART for the treatment of gMG in Canada
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
argenx receives positive CHMP opinion for SC injectable formulation of efgartigimod for the treatment of gMG
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary
argenx to participate in upcoming investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary
argenx SE announces its half-year 2023 financial results and second-quarter business update. VYVGART® global net product sales reached $269 million in Q2 2023. The company launched VYVGART Hytrulo in the U.S. and shipped the first vials in July. Topline results from ADVANCE-SC and ADDRESS studies expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
argenx, a global immunology company, will host a conference call on July 27, 2023, to discuss its half year 2023 financial results and provide a second quarter business update. The webcast can be accessed on the argenx website. Dial-in numbers are provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
argenx SE has announced the pricing of a global offering of ordinary shares and American Depository Shares (ADSs), with anticipated total gross proceeds of approximately $1.1 billion. The offering includes the sale of 1,580,981 ADSs at a price of $490.00 per ADS and the sale of 663,918 ordinary shares at a price of €436.37 per ordinary share. The offering is expected to close on July 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
Rhea-AI Summary
argenx announces positive results from the ADHERE study evaluating VYVGART Hytrulo in adults with CIDP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.79%
Tags
none

FAQ

What is the current stock price of argenx SE American Depositary Shares (ARGX)?

The current stock price of argenx SE American Depositary Shares (ARGX) is $623.82 as of December 20, 2024.

What is the market cap of argenx SE American Depositary Shares (ARGX)?

The market cap of argenx SE American Depositary Shares (ARGX) is approximately 37.1B.

What does argenx SE specialize in?

argenx SE specializes in developing treatments for severe autoimmune diseases and cancer using advanced antibody engineering technology.

What is Vyvgart?

Vyvgart (efgartigimod) is an argenx-developed treatment for generalized myasthenia gravis, approved in the U.S., Europe, and Japan.

When was Vyvgart approved in the U.S.?

Vyvgart was approved by the U.S. FDA in December 2021.

What are argenx's recent projects?

argenx is advancing clinical studies for VYVGART Hytrulo in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Who can be contacted for more information about argenx?

For more information, contact Ben Petok (BPetok@argenx.com), Alexandra Roy (US - ARoy@argenx.com), or Lynn Elton (EU - LElton@argenx.com).

Where is argenx SE located?

argenx SE is a Dutch company with a global presence in the biopharmaceutical industry.

What makes argenx's technology unique?

argenx leverages advanced antibody engineering to develop innovative treatments for rare and severe autoimmune diseases and cancer.

What is the focus of argenx's R&D?

argenx focuses on creating and advancing novel antibody-based medicines targeting autoimmune diseases and cancer.

How does argenx fund its operations?

argenx funds its operations through strategic partnerships, a robust pipeline, and strong financial management.

What is VYVGART Hytrulo?

VYVGART Hytrulo is an investigational therapy being studied by argenx for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

argenx SE American Depositary Shares

Nasdaq:ARGX

ARGX Rankings

ARGX Stock Data

37.14B
59.47M
0%
59.76%
3.47%
Biotechnology
Healthcare
Link
United States of America
Amsterdam